The vaccine successfully stimulated the production of antibodies and T cells, and the scientists did not find any serious side effects.
Tests of the SARS-CoV-2 coronavirus vaccine, developed by scientists at the University of Oxford, have shown that the drug stimulates the production of antibodies and T cells necessary to protect against infection. Its results were published in the journal Lancet… The UK authorities have already placed an order for the production of 100 million doses of the drug.
Clinical trials of the vaccine involving 1,077 volunteers have shown that the drug induces a strong immune response and has few side effects. T cells (T lymphocytes) are produced within 14 days after vaccination, antibodies within 28 days.
Scientists found the test results promising, but warned that it will be possible to confirm the reliability of the vaccine’s protective properties only after larger studies that are underway right now. However, the UK has already ordered the first batch of vaccines – 100 million doses, the BBC reports.
According to the lead author of the research, professor at Oxford University Andrew Pollard, the new drug is a vaccine based on the chimpanzee adenovirus (ChAdOx1), which is safe for humans. This virus is genetically modified to encode the coronavirus spike protein. When it enters the human body, it causes cells to produce the coronavirus protein and “trains” the immune system to recognize it.
“The immune system has two ways to detect and attack pathogens – antibody and T cell responses. The vaccine is designed to cause both reactions, so it can attack the virus as it circulates in the body and attack the infected cells. We hope that the immune system will “remember” the virus and will protect people for a long time, “says the scientist.
Currently, about a dozen potential vaccines against coronavirus are undergoing clinical trials in humans around the world. The largest pharmaceutical giants are in the race for the vaccine: AstraZeneca, Pfizer, BioNtech, Johnson & Johnson, Merck, Moderna, Sanofi and CanSino Biologics. In Russia, the development of a vaccine is carried out by the National Research Center for Epidemiology and Microbiology. N.F. Gamalei. The vaccine has already been administered to the first group of volunteers.